RxDoctor Payments Data

Alicia Wettrick

Family · Indianapolis, INNPI 1285649913

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $69,560 of the $71,622 with a category attached, or 97.1%. Organon accounts for 89.2% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2023 at $27,723 and has fallen 97.3% since, to $751 in 2025. Among family clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$71,622in general payments, 2019–2025

Across 152 payments — averaging $471.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Organon$64K
  • Merck$6K
  • Astellas Pharma US Inc$472
  • Hologic Sales And Service, LLC$336
  • Exeltis, USA Inc.$271
  • Mayne Pharma Commercial LLC$143
  • plus $411 from 10 others

What the payments were for

  • Speaking & faculty fees$69,56097%
  • Travel & lodging$2810%
  • Food & beverage$1,7822%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$71,622 in reported general payments places this provider in the 95th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$1,872
Medicare patients
23
Services billed
38

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Estradiol29$2,296

Paid to pharmacies, not to this prescriber.

Other family in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →